[go: up one dir, main page]

PT719859E - Anticorpo monoclonal anti-alfa v-integrina - Google Patents

Anticorpo monoclonal anti-alfa v-integrina

Info

Publication number
PT719859E
PT719859E PT95119233T PT95119233T PT719859E PT 719859 E PT719859 E PT 719859E PT 95119233 T PT95119233 T PT 95119233T PT 95119233 T PT95119233 T PT 95119233T PT 719859 E PT719859 E PT 719859E
Authority
PT
Portugal
Prior art keywords
integrina
monoclonal antibody
alpha monoclonal
alpha
antibody
Prior art date
Application number
PT95119233T
Other languages
English (en)
Inventor
Simon Goodman
Jaume Piulats
Francesc Mitjans
Jaume Adan
Elisabet Rosell
Diane Hahn
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8216547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT719859(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PT719859E publication Critical patent/PT719859E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT95119233T 1994-12-20 1995-12-06 Anticorpo monoclonal anti-alfa v-integrina PT719859E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94120165 1994-12-20

Publications (1)

Publication Number Publication Date
PT719859E true PT719859E (pt) 2003-11-28

Family

ID=8216547

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95119233T PT719859E (pt) 1994-12-20 1995-12-06 Anticorpo monoclonal anti-alfa v-integrina

Country Status (26)

Country Link
US (1) US5985278A (pt)
EP (1) EP0719859B1 (pt)
JP (1) JP3898245B2 (pt)
KR (1) KR100450368B1 (pt)
CN (1) CN1117763C (pt)
AR (1) AR001778A1 (pt)
AT (1) ATE244306T1 (pt)
AU (1) AU710234B2 (pt)
BR (1) BR9505980B1 (pt)
CA (1) CA2165573C (pt)
CO (1) CO4480042A1 (pt)
CZ (1) CZ290477B6 (pt)
DE (1) DE69531187T2 (pt)
DK (1) DK0719859T3 (pt)
ES (1) ES2202336T3 (pt)
FI (1) FI118536B (pt)
HU (1) HU221061B1 (pt)
NO (1) NO321186B1 (pt)
PL (1) PL182961B1 (pt)
PT (1) PT719859E (pt)
RU (1) RU2205223C2 (pt)
SI (1) SI0719859T1 (pt)
SK (1) SK284932B6 (pt)
TR (1) TR199501614A2 (pt)
UA (1) UA40621C2 (pt)
ZA (1) ZA9510806B (pt)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4134497A (en) * 1996-09-03 1998-03-26 Chugai Seiyaku Kabushiki Kaisha Anti-integrin alpha3 antibody complexes
ES2321991T3 (es) * 1996-12-09 2009-06-15 Merck Patent Gmbh Receptor de adhesion alfavbet3 recombinante soluble.
ES2311131T3 (es) * 1997-08-08 2009-02-01 The Regents Of The University Of California Tratamiento de la fibrosis hepatico con anticuerpos contra la integrina alfa-v-beta6.
ATE322508T1 (de) * 1998-01-23 2006-04-15 Merck Patent Gmbh Verwendung des antikörpers 271.14d9.f8 (dsm acc2331) um die bindung zwischen alphavbeta6- integrin und fibronectin in vitro zu hemmen
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
US7064180B2 (en) 2000-07-31 2006-06-20 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
US7153944B2 (en) * 2000-07-31 2006-12-26 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
US7323552B2 (en) * 2000-07-31 2008-01-29 The General Hospital Corporation Variant integrin polypeptides and uses thereof
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
AU2002306651B2 (en) * 2001-03-02 2007-12-13 Medimmune, Llc Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav Beta3 antagonists
PT1381384E (pt) 2001-04-24 2011-09-01 Merck Patent Gmbh Terapia de combinação usando agentes anti-angiogénicos e tnfa
AU2002312566A1 (en) * 2001-07-09 2003-01-29 Elan Pharmaceuticals, Inc. Methods of inhibiting amyloid toxicity
US7829087B2 (en) * 2001-07-09 2010-11-09 Elan Pharmaceuticals, Inc. Methods of treating cognitive impairment
US20050084489A1 (en) * 2002-03-04 2005-04-21 Wilder Ronald L. Methods of preventing or treating disorders by administering and integrin alphanubeta3 antagonist in combination with an HMG-CoA reductase inhibitor or a bisphosphonate
AU2003217930A1 (en) * 2002-03-04 2003-09-22 Medimmune, Llc The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
US7465449B2 (en) * 2002-03-13 2008-12-16 Biogen Idec Ma Inc. Anti-αvβ6 antibodies
CN100509851C (zh) * 2002-03-13 2009-07-08 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
WO2003087340A2 (en) * 2002-04-12 2003-10-23 Raven Biotechnologies, Inc. Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
EP1499352A4 (en) 2002-04-12 2006-10-11 Medimmune Inc ANTI-INTERLEUKIN-9 RECOMBINANT ANTIBODIES
JP2006516635A (ja) * 2003-01-30 2006-07-06 メディミューン，インコーポレーテッド インテグリンαｖβ３アンタゴニストの使用
KR20120035234A (ko) 2003-04-11 2012-04-13 메디뮨 엘엘씨 재조합 ｉｌ?９ 항체 및 그의 용도
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
JP2008518023A (ja) 2004-10-27 2008-05-29 メディミューン，インコーポレーテッド 同族抗原に対する親和性を改変することによる抗体特異性の調節
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
NZ615012A (en) * 2006-03-21 2015-11-27 Genentech Inc Combinatorial therapy involving alpha5beta1 antagonists
WO2008008315A2 (en) 2006-07-10 2008-01-17 Biogen Idec Ma Inc. Compositions and methods for inhibiting growth of smad4-deficient cancers
US8637469B2 (en) 2006-07-11 2014-01-28 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
CA3177366A1 (en) 2006-08-10 2008-02-21 Roy C. Levitt Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
US20090196913A1 (en) * 2007-05-11 2009-08-06 Ken Shi Kun Huang Anti-Alpha-V Immunoliposome Composition, Methods, and Uses
US20090175784A1 (en) * 2007-05-11 2009-07-09 Joshua Goldstein Anti-Alpha V Immunoliposome Composition, Methods, and Uses
WO2009010290A2 (en) * 2007-07-17 2009-01-22 Merck Patent Gmbh Engineered anti-alpha v- integrin hybrid antibodies
US7973138B2 (en) 2007-09-26 2011-07-05 Genentech, Inc. Antibodies
CA2747937C (en) 2008-12-23 2019-02-26 Merck Patent Gmbh Biomarkers for inhibitors with anti-angiogenic activity
CN102365297B (zh) 2009-03-25 2014-10-29 霍夫曼-拉罗奇有限公司 新型抗-α5β1抗体及其应用
US20120263739A1 (en) 2009-11-13 2012-10-18 Merck Patent Gmbh Anti integrin antibodies linked to nanoparticles loaded with chemotherapeutic agents
WO2011103490A2 (en) * 2010-02-18 2011-08-25 The Regents Of The University Of California INTEGRIN αVβ8 NEUTRALIZING ANTIBODY
WO2012027745A1 (en) * 2010-08-27 2012-03-01 University Of Miami Treatment of renal diseases
WO2012107211A1 (en) 2011-02-11 2012-08-16 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of prostate cancer
US20130066055A1 (en) 2011-04-21 2013-03-14 Bayer Intellectual Property Gmbh New binder-drug conjugates (adcs) and use thereof
BR112014003501B1 (pt) * 2011-08-17 2022-02-08 The Regents Of The University Of California Anticorpo humanizado que se liga especificamente à integrina alfa-v beta-8, seu uso na redução da sinalização de tgfbeta, composição farmacêutica, bem como método para detectar a presença de uma célula que expressa alfa-v beta-8
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
PE20160996A1 (es) 2013-12-23 2016-11-09 Bayer Pharma AG Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp
JP7372025B2 (ja) 2014-09-17 2023-10-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 固形がんおよび／またはその転移を処置する方法、そのための薬剤、ならびに固形がんおよび／またはその転移処置の臨床転帰を予測する方法
KR20170055540A (ko) 2014-09-17 2017-05-19 메르크 파텐트 게엠베하 뼈 전이 질환 치료 방법, 그에 따른 약제, 및 뼈 전이 질환 치료의 임상 결과 예측 방법
AU2016282723B2 (en) 2015-06-22 2021-09-23 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (ADCs) and antibody prodrug conjugates (APDCs) with enzymatically cleavable groups
US10973923B2 (en) 2015-06-23 2021-04-13 Bayer Pharma Aktiengesellschaft Site specific homogeneous with KSP inhibitors
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
US20190144547A1 (en) 2015-11-23 2019-05-16 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
SG10202008909VA (en) 2016-03-24 2020-10-29 Bayer Pharma AG Prodrugs of cytotoxic active agents having enzymatically cleavable groups
EP3919518A1 (en) 2016-06-15 2021-12-08 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
EP3510407A1 (en) 2016-09-08 2019-07-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating nephrotic syndrome
CA3047522A1 (en) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Specific antibody drug conjugates (adcs) having ksp inhibitors
KR20190099250A (ko) 2016-12-21 2019-08-26 바이엘 악티엔게젤샤프트 효소적으로 절단가능한 기를 갖는 세포독성 활성제의 전구약물
KR102628678B1 (ko) 2016-12-21 2024-01-25 바이엘 파마 악티엔게젤샤프트 효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc)
KR101961715B1 (ko) 2018-07-18 2019-03-25 (주) 삼진정밀 고효율 수처리장치
AU2019362602A1 (en) 2018-10-19 2021-06-03 Merck Patent Gmbh Abituzumab for the treatment of colorectal cancer
KR101999620B1 (ko) 2019-03-26 2019-07-12 조용진 부상슬러지 및 침전슬러지의 동시처리장치
MA55613A (fr) * 2019-04-08 2022-02-16 Biogen Ma Inc Anticorps anti-intégrine et leurs utilisations
JP2023503851A (ja) 2019-11-15 2023-02-01 プライアント・セラピューティクス・インコーポレイテッド インテグリン活性化のための組成物および方法
CN117143241B (zh) * 2023-10-26 2024-02-23 迈威(上海)生物科技股份有限公司 与人整合素蛋白itgav/itgb8特异性结合的单克隆抗体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0633945B1 (en) * 1992-04-03 1998-12-30 Genentech, Inc. ANTIBODIES TO ALPHAvBETA3 INTEGRIN
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis

Also Published As

Publication number Publication date
DE69531187T2 (de) 2004-04-22
AU4042195A (en) 1996-06-27
CA2165573C (en) 2011-03-29
DE69531187D1 (de) 2003-08-07
FI956112L (fi) 1996-06-21
ATE244306T1 (de) 2003-07-15
SK284932B6 (sk) 2006-02-02
BR9505980A (pt) 1997-12-23
UA40621C2 (uk) 2001-08-15
JPH08231597A (ja) 1996-09-10
RU2205223C2 (ru) 2003-05-27
HUT74828A (en) 1997-02-28
BR9505980B1 (pt) 2010-02-23
AU710234B2 (en) 1999-09-16
CZ328895A3 (en) 1996-09-11
KR100450368B1 (ko) 2005-01-31
DK0719859T3 (da) 2003-10-20
KR960022562A (ko) 1996-07-18
EP0719859A1 (en) 1996-07-03
CO4480042A1 (es) 1997-07-09
AR001778A1 (es) 1997-12-10
US5985278A (en) 1999-11-16
FI956112A0 (fi) 1995-12-19
PL182961B1 (pl) 2002-05-31
NO955167L (no) 1996-06-21
ZA9510806B (en) 1996-05-30
JP3898245B2 (ja) 2007-03-28
NO321186B1 (no) 2006-04-03
CN1139115A (zh) 1997-01-01
NO955167D0 (no) 1995-12-19
HU9503638D0 (en) 1996-02-28
EP0719859B1 (en) 2003-07-02
CZ290477B6 (cs) 2002-07-17
ES2202336T3 (es) 2004-04-01
HU221061B1 (hu) 2002-07-29
SK159295A3 (en) 1996-07-03
FI118536B (fi) 2007-12-14
CA2165573A1 (en) 1996-06-21
PL311926A1 (en) 1996-06-24
TR199501614A2 (tr) 1996-07-21
CN1117763C (zh) 2003-08-13
SI0719859T1 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
PT719859E (pt) Anticorpo monoclonal anti-alfa v-integrina
DK1516629T3 (da) Humaniseret anti-CD-11a antibodies
FI965032L (fi) Interleukiini-5-spesifisiä yhdistelmä-vasta-aineita
DE69920897D1 (de) Monoklonale antikörper mit verringerter immunisierungsfähigkeit
DK145493D0 (da) Antistof
IL128406A0 (en) Monoclonal antibodies
FI963004L (fi) Vasta-aineen muodostumista kiihottavia monoklonaalivasta-aineita
FI964845L (fi) CD44v6:n vastaiset monoklonaaliset vasta-aineet
FI945865L (fi) Glykoprofeiini P:lle kohdistettuja monoklonaalisia vasta-aineita
DE69828154D1 (de) Anti-alphavbeta3 humanizierte monoklonale antikörper
DE69738312D1 (de) Hepatitis b monoklonale antikörper
NO981272D0 (no) Humanisert anti-human-Fas-antistoff
BR9509902A (pt) Fragmentos de anticorpos monoclonais apresentando atividade imunosupressante
GB9718911D0 (en) Monoclonal antibodies
ZA951113B (en) Tumor assosiated monoclonal antibody 123av16
DE69427850D1 (de) Monoklonaler antikörper gegen mucoglykoprotein
EP1106701A4 (en) MONOCLONAL ANTIBODY DIRECTED AGAINST DYNAMIC TRYPSIN
NO985281D0 (no) Monoklonalt antihumant MP52-antistoff
DE69324928D1 (de) Monoklonaler antikörper
BR1100555B1 (pt) anticorpos monoclonais humanizados.
GB9615027D0 (en) Monoclonal antibodies
ZA954678B (en) Monoclonal antibody against cd44v6
SI0742795T1 (en) Immuno-stimulatory monoclonal antibodies
GB9212074D0 (en) Monoclonal antibody
IE901210L (en) Monoclonal antibody